BridgeBio Pharma (BBIO) Goodwill & Intangibles (2018 - 2026)

BridgeBio Pharma has disclosed Goodwill & Intangibles across 8 years of filings, most recently posting $27.4 million for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $27.4 million, down 1.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.4 million (down 1.59% YoY), and the FY2025 annual result was $28.1 million, up 17.35% from the prior year.
• Goodwill & Intangibles came in at $27.4 million for Q1 2026 at BridgeBio Pharma, down from $28.1 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $30.5 million in Q1 2022 to a low of $23.9 million in Q4 2024.
• The 5-year median for Goodwill & Intangibles is $27.8 million (2025), against an average of $27.5 million.
• Peak annual rise in Goodwill & Intangibles reached 91.41% in 2022, while the deepest fall reached 36.56% in 2022.
• BridgeBio Pharma's Goodwill & Intangibles stood at $28.7 million in 2022, then fell by 8.33% to $26.3 million in 2023, then dropped by 9.09% to $23.9 million in 2024, then advanced by 17.35% to $28.1 million in 2025, then fell by 2.56% to $27.4 million in 2026.
• The last three Goodwill & Intangibles figures came in at $27.4 million (Q1 2026), $28.1 million (Q4 2025), and $28.8 million (Q3 2025), per Business Quant data.